Premium
P4‐006: Virgil Electronic Clinical Outcome Assessments (Ecoa) Platform: Improving Signal Detection in Alzheimer's Disease Clinical Trials
Author(s) -
Negash Selam,
Boehm Peter,
Steele Shelly,
Sorantin Peter,
Randolph Christopher
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.2095
Subject(s) - clinical trial , medicine , disease , clinical endpoint , cognitive impairment , cohort
age, education level, and gender. There was a significant e4 x age interaction (p1⁄40.03). We found no associations between e4+ and processing speed or attention, or between family history of e4+ and cognitive test scores. There were significant associations between self-reported memory problems and both e4+ (p<0.001) and family history of e4+ (p<0.001). We identified 2032 “likely prodromal” and 6227 “likely preclinical” participants for AD trials. Of those likely eligible participants who reported their e4 genotype (n1⁄41650), 16% of prodromal and 4% of preclinical were e4+. Conclusions: In a large, novel, internet-based cohort, self-reported e4 is associated with online memory test scores in younger participants, and cognitively-normal participants. In the general cohort, age eclipses the effects of e4 genotype on memory scores. Self-reportedmemory problems are strongly associated with e4 evenwhen controlling for other variables. BHR participants identified as likely prodromal have four times greater prevalence of e4+ than older adults with normal cognitive test scores. Self-report of e4 in BHR can be used to prescreen for AD trials requiring e4, facilitate AD trials, and accelerate development of new AD treatments.